HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $4,653,000 | -9.7% | 299,969 | 0.0% | 0.03% | -8.6% |
| Q2 2019 | $5,153,000 | +6.7% | 299,969 | 0.0% | 0.04% | +12.9% |
| Q1 2019 | $4,830,000 | +10.0% | 299,969 | 0.0% | 0.03% | -13.9% |
| Q4 2018 | $4,389,000 | -46.3% | 299,969 | -33.3% | 0.04% | -33.3% |
| Q3 2018 | $8,176,000 | -62.3% | 449,969 | -65.0% | 0.05% | -66.9% |
| Q2 2018 | $21,660,000 | -30.1% | 1,283,929 | -18.8% | 0.16% | -38.0% |
| Q1 2018 | $30,980,000 | -3.3% | 1,581,424 | 0.0% | 0.26% | -5.4% |
| Q4 2017 | $32,040,000 | +16.6% | 1,581,424 | 0.0% | 0.28% | +24.7% |
| Q3 2017 | $27,469,000 | +35.5% | 1,581,424 | 0.0% | 0.22% | +26.0% |
| Q2 2017 | $20,274,000 | +12.4% | 1,581,424 | +13.6% | 0.18% | +19.6% |
| Q1 2017 | $18,034,000 | +31.2% | 1,391,507 | 0.0% | 0.15% | +9.6% |
| Q4 2016 | $13,748,000 | -34.3% | 1,391,507 | -19.6% | 0.14% | -28.9% |
| Q3 2016 | $20,911,000 | +31.8% | 1,731,057 | -5.8% | 0.19% | +14.5% |
| Q2 2016 | $15,862,000 | -13.3% | 1,838,057 | -4.8% | 0.17% | -14.0% |
| Q1 2016 | $18,287,000 | -45.4% | 1,931,057 | 0.0% | 0.19% | -30.3% |
| Q4 2015 | $33,465,000 | +29.0% | 1,931,057 | 0.0% | 0.28% | +15.4% |
| Q3 2015 | $25,934,000 | -40.5% | 1,931,057 | 0.0% | 0.24% | -37.2% |
| Q2 2015 | $43,603,000 | +35.8% | 1,931,057 | -14.1% | 0.38% | +43.1% |
| Q1 2015 | $32,104,000 | +19.8% | 2,248,152 | -19.0% | 0.27% | -2.2% |
| Q4 2014 | $26,790,000 | +6.0% | 2,776,143 | 0.0% | 0.27% | -14.2% |
| Q3 2014 | $25,263,000 | -7.9% | 2,776,143 | 0.0% | 0.32% | -5.4% |
| Q2 2014 | $27,428,000 | -62.1% | 2,776,143 | -51.3% | 0.34% | -63.5% |
| Q1 2014 | $72,366,000 | -23.3% | 5,698,139 | -9.5% | 0.92% | -30.8% |
| Q4 2013 | $94,392,000 | +21.8% | 6,297,026 | -10.3% | 1.33% | +20.8% |
| Q3 2013 | $77,474,000 | +48.7% | 7,017,608 | +7.1% | 1.10% | +6.9% |
| Q2 2013 | $52,098,000 | – | 6,553,150 | – | 1.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |